Ocular Myasthenia Gravis

Ocular myasthenia gravis (OMG) is a form of myasthenia gravis in which muscle weakness is limited to the eye muscles. It causes drooping eyelids (ptosis) and double vision without affecting other muscles in the body.

Questions about your diagnosis? Contact our office

Understanding Ocular Myasthenia

Myasthenia gravis is an autoimmune disease where antibodies attack the neuromuscular junction, where nerves connect to muscles. In ocular myasthenia, this attack affects only the muscles that move the eyes and eyelids.

The eye muscles may be particularly vulnerable because:

• They contract rapidly and frequently
• They have fewer acetylcholine receptors per junction
• They lack the ability to increase receptor density

Symptoms

Ptosis (Drooping Eyelid)

• One or both eyelids
• Often asymmetric
• Worse later in day or with fatigue
• May shift from one eye to other
• Improves with rest or sleep

Diplopia (Double Vision)

• Variable pattern
• May mimic any cranial nerve palsy
• Often inconsistent day to day
• Worse with sustained gaze
• Improves with rest

Fatigue Pattern

• Morning: Symptoms better after sleep
• Evening: Symptoms worse after use
• Fatigability: Worsens with sustained activity

Diagnosis

Clinical Examination

• Sustained upgaze test (fatigable ptosis)
• Checking for Cogan's lid twitch
• Ice pack test: improvement with cooling

The ice pack test is a quick bedside clue when ptosis is present. Single-fiber EMG can provide additional evidence when the examination and antibody results leave uncertainty.

Antibody Testing

• AChR antibodies: May be negative in ocular MG
• Anti-MuSK antibodies: Occasionally positive
• Negative antibodies don't rule out ocular MG

Electrodiagnostic Testing

• Repetitive nerve stimulation
• Single-fiber EMG (most sensitive)
• May be normal in purely ocular disease

Other Tests

• CT chest (rule out thymoma)
• Thyroid function tests
• Blood tests

Ocular Myasthenia Gravis Treatment

Symptomatic Treatment

Pyridostigmine (Mestinon)

• Often the first medication used for symptom relief
• Improves neuromuscular transmission
• Dosing is individualized because benefit can vary between ptosis and double vision
• Side effects: GI cramping, diarrhea

Immunosuppression

May be considered when pyridostigmine does not provide adequate control:

• Prednisone
• Azathioprine
• Mycophenolate
• Rituximab: sometimes considered by specialists for refractory disease

Steroids and other immunotherapies require monitoring for adverse effects. The evidence for preventing generalization is largely observational, so treatment decisions should account for symptom burden, antibody status, other medical conditions, and medication risks.

Ptosis Management

• Ptosis crutches on glasses
• Eyelid tape
• Ptosis surgery in stable cases

Diplopia Management

• Prism glasses
• Occlusion (patch or frosted lens)
• Strabismus surgery if stable

Thymectomy

• Thymectomy may benefit some patients
• Especially if thymoma present
• Role in purely ocular MG still debated

Ocular vs. Generalized Myasthenia Gravis

Ocular myasthenia affects the eyelids and muscles that move the eyes. Generalized myasthenia gravis also causes weakness outside the eye region. Symptoms can include difficulty chewing or swallowing, a weak or slurred voice, neck or limb weakness, and shortness of breath.

At follow-up visits, tell your clinician about changes in speech, chewing, swallowing, breathing, neck strength, or arm and leg strength. These symptoms can change the diagnosis, monitoring plan, and treatment.

Progression Risk

Older studies and systematic reviews estimate that 50% to 60% of people who present with ocular myasthenia later develop generalized disease, with most progression occurring within the first 2 years. Estimates vary by study population, antibody testing, diagnostic criteria, and treatment exposure.

Factors suggesting higher risk:

• Positive AChR antibodies
• Abnormal repetitive nerve stimulation
• Thymoma on imaging
• Older age at onset

If symptoms remain purely ocular after 2 years, the risk becomes lower, although later generalization can still occur.

Living with Ocular Myasthenia

For a practical overview of symptom tracking, driving, work, and warning signs, see our ocular myasthenia daily-management guide.

Managing Fatigue

• Schedule rest breaks
• Avoid sustained reading/screen time
• Use audiobooks
• Position reading material at eye level

Driving Considerations

• Double vision may affect driving
• Discuss with doctor
• May need prism glasses or patching

Activity Modifications

• Avoid extreme heat
• Adequate sleep important
• Stress management helpful

When to Seek Urgent Care

Frequently Asked Questions

Will my ocular myasthenia become generalized?

Published estimates vary, but older studies suggest roughly half of patients develop generalized symptoms, usually within 2 years. Your individual risk depends on factors such as antibody results, electrodiagnostic findings, age, thymus findings, and treatment history.

Why are my antibody tests negative?

Antibody tests are less sensitive in ocular myasthenia than in generalized disease. A negative result does not exclude ocular myasthenia, so clinicians may use the examination, ice pack test, and electrodiagnostic testing together.

Can I still drive?

This depends on whether your double vision is controlled with prisms, patching, or medication. Discuss with your doctor and follow local regulations.

Is myasthenia gravis hereditary?

No, myasthenia gravis is not directly inherited. However, there may be some genetic susceptibility to autoimmune diseases in general.

References

1. American Academy of Ophthalmology EyeWiki. Myasthenia Gravis.
2. MedlinePlus. Myasthenia Gravis.
3. Narayanaswami P, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96(3):114-122.
4. Benatar M, Kaminski H. Medical and surgical treatment for ocular myasthenia. Cochrane Database Syst Rev. 2012;(12):CD005081.
5. Myasthenia Gravis Foundation of America. General MG Management.